AGC and Neusignal Therapeutics partner on Alzheimer candidate NTX-083
- AGC provided integrated CDMO support for NTX-083 covering process development, GMP manufacturing, and regulatory support.
- AGC established the drug substance manufacturing process and completed CMC documentation for a US IND application.
- NTX-083 is scheduled to enter clinical trials in the United States in 2026.
- Process development was led by AGC’s Yokohama Technical Center with GMP production at the Chiba Site to ensure a smooth transition to clinical supply.
Collaboration scope
AGC supplied end-to-end small‑molecule CDMO support for NTX‑083, an Alzheimer’s disease drug candidate, handling process development, GMP manufacturing and regulatory support from early development stages. AGC established the drug substance manufacturing process and completed the CMC documentation required for a US IND application.
Operational execution
The programme combined AGC’s Yokohama Technical Center for process development with its Chiba Site for GMP manufacturing to enable a smooth transition from development to clinical supply.
Regulatory and timeline
AGC prepared the documentation needed to support an IND filing with the US FDA. NTX‑083 is planned to enter clinical trials in the United States in 2026.
Strategic context
The work aligns with AGC’s medium‑term plan, AGC plus‑2026, and its stated “Well‑being” objective; AGC positions its Life Science CDMO services as part of efforts to support drug discovery and contribute to healthcare supply.
Source: AGC
